[Pharmacogenetics of methemoglobin-producing agents].
D001205:Ascorbic Acid / Q000627:therapeutic use; D002704:Chlorates / Q000009:adverse effects; D042966:Cytochrome-B(5) Reductase / Q000378:metabolism; D006801:Humans; D008706:Methemoglobin / Q000096:biosynthesis*; D008708:Methemoglobinemia / Q000139:chemically induced* / Q000188:drug therapy; D008751:Methylene Blue / Q000627:therapeutic use; D009573:Nitrites / Q000009:adverse effects; D010083:Oxidants, Photochemical / Q000009:adverse effects*; D010597:Pharmacogenetics; D010615:Phenacetin / Q000009:adverse effects; D011809:Quinones / Q000009:adverse effects; D013268:Stimulation, Chemical; D062367:ortho-Aminobenzoates / Q000627:therapeutic use
D002704:Chlorates; D009573:Nitrites; D010083:Oxidants, Photochemical; D011809:Quinones; D062367:ortho-Aminobenzoates; D008706:Methemoglobin; D042966:Cytochrome-B(5) Reductase; D010615:Phenacetin; D001205:Ascorbic Acid; D008751:Methylene Blue
Farmakogenetika metgemoglobinobrazuiushchikh sredstv.